Purpose Although a substantial proportion of patients with heart failure (HF) have anemia, there is a paucity of data evaluating the impact of anemia on clinical outcome in CRT patients. Our goal was to examine the ability of baseline hemoglobin (Hb) level and change in Hb level over time to predict clinical 2-year outcome and echocardiographic response to CRT. Methods Three hundred consecutive CRT patients (median 72 years [interquartile range (IQR) 16 years], 19 % female) with baseline and follow-up hematological profiles available were examined. Baseline anemia was defined as Hb <12 g/dL in women and <13 g/dL in men, and patients were grouped into equal quartiles based on change in Hb. Two-year clinical outcome was determined using a composite endpoint that included HF hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause mortality. Echocardiographic reverse remodeling was examined at 6-month follow-up. Results One hundred fifty-one anemic patients were compared to 149 non-anemic patients. Changes in left ventricular dimensions and ejection fraction were similar for both groups. Univariate predictors of 2-year clinical outcome included baseline creatinine level, diuretic usage, and anemia; in multivariable regression, baseline anemia was an independent predictor for outcome (hazard ratio [HR] 1.79, 95 % confidence interval [CI] [1.22-2.63], p=0.003). The quartile with the most negative change in Hb concentration over time (≤−1.00 g/dL) had poorer event-free 2-year survival (HR 1.84, CI [1.13-3.00], p=0.014). Conclusions Baseline anemia and early postimplantation decline in Hb levels are associated with a worse 2-year prognosis in CRT patients, even though the magnitude of left ventricular reverse remodeling is similar compared to non-anemic patients.
Introduction
Cardiac resynchronization therapy (CRT) is now standardly used in adjunct to pharmacological treatments to manage patients with symptomatic heart failure (HF) in New York Heart Association (NYHA) classes II-IV and wide QRS [1] [2] [3] [4] . Despite CRT's overall effectiveness, up to 30 % of patients do not demonstrate favorable clinical response [1, 2] . Currently, narrow QRS complex on ECG, right bundle branch block (RBBB), ischemic cardiomyopathy (ICM), male gender, and HF comorbidities such as chronic kidney disease Ramkumar V. Venkateswaran and Carolyn Freeman contributed equally to this work.
Electronic supplementary material
The online version of this article (doi:10.1007/s10840-015-0062-9) contains supplementary material, which is available to authorized users.
(CKD) have all been established as predictors of CRT nonresponse [5, 6] .
Another common comorbidity associated with HF is anemia. The WHO defines anemia as a hemoglobin (Hb) content <13 g/dL in men and <12 g/dL in women, although many HF and anemia studies define anemia as Hb <12 or 12.5 g/dL for both genders alike [7, 8] . Anemia affects a large proportion of the HF population, with a prevalence ranging from 15 to 61 % in clinical trials and large HF registries [9] [10] [11] . Furthermore, both anemia and decreases in Hb level over time have been shown to be independent predictors of morbidity and mortality in HF patients [8, 9, [12] [13] [14] . CRT significantly improves left ventricular systolic function in selected heart failure patients and has a theoretical potential to simultaneously improve secondary renal dysfunction and anemia, but there is currently no data reflecting the correlation between anemia and the outcome of the subset of HF patients undergoing CRT.
Thus, the goal of this institutional retrospective observational study was to determine whether baseline anemia and/ or change in Hb levels over time correlated with poor clinical outcomes after CRT.
Methods

Patient profile
The population included 300 consecutive patients who underwent CRT device implantation and had follow-up care at Massachusetts General Hospital between January 2003 and June 2011. The only criterion for inclusion was the presence of hemoglobin assessment (g/dL) in blood tests immediately preimplantation and between 3 and 9 months postimplantation. The follow-up hemoglobin measurement was in most cases done at the 6 months postoperative time period, and the first available hemoglobin value was used. As this was a retrospective study, no protocol was followed for the collection of blood tests. Blood tests were performed at the discretion of following physicians, and only those patients that met the inclusion criteria were included in the study. There were no other exclusion criteria. All patients met the current approved guidelines for CRT therapy [15] . Routine baseline evaluation, including determination of HF etiology, echocardiographic measurements, NYHA classification, and hematological profiles, was performed for each individual.
Outcome measures
Clinical outcome was measured as a combined primary endpoint including HF hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause mortality within 2 years of implantation. Secondary endpoint was a combination of all-cause mortality, LVAD, or heart transplant within 2 years. Left ventricular systolic and diastolic dimensions were assessed in the standard 2D parasternal long-axis projection, and ejection fraction was calculated using the modified Simpson's biplane method in the apical two-and four-chamber views.
Statistical analysis
The patient population was divided into two groups: anemic and non-anemic; the anemic group was defined as having preimplantation Hb≤12.0 g/dL in females and Hb≤13.0 g/ dL in males. Means and standard deviations were calculated for normally distributed variables, and the baseline characteristics of the two groups were compared using the independent t test for continuous variables and the Pearson's chi-squared test for categorical variables. For non-normally distributed variables, medians and interquartile ranges were determined, and the Mann-Whitney U test was used to compare differences between the two groups. Univariate Cox regression analysis identified the baseline variables that independently related to 2-year survival outcomes. Subsequently, a Cox proportional hazard multivariate regression model accounted for the confounding variables and produced a hazard ratio for baseline anemia. The threshold for inclusion into the multivariate model was p=0.2. Gender was predetermined to be included as an important variable.
The dynamic component of the study, defined by the change in Hb concentration from baseline to follow-up, was assessed by dividing the group into quartiles based on change in Hb from baseline to follow-up. Cox regression analysis and Kaplan-Meier survival curves were then done as a landmark analysis, excluding all events prior to the time of follow-up hemoglobin sampling. Log-rank test was used to compare 2-year survival free of the composite endpoint. SPSS version 22 was used to carry out the data analysis, and a two-sided p value ≤0.05 was accepted as statistically significant.
Results
In the cohort of 589 consecutive patients, a total of 300 patients met the inclusion criteria of the study and 269 patients were excluded due to lack of follow-up hemoglobin assessment after 3-9 months postimplantation. The average followup time for the hematological profile was 5.1±1.7 months postimplantation, and baseline characteristics for the patients in the study are shown in Table 1 . The study group was representative of a typical heart failure population eligible for CRT; 81 % were male, mean left ventricular ejection fraction was 24 %, 63 % had NYHA class III symptomology, and 47 % had left bundle branch block (LBBB). Differences between the anemic and normal groups can be seen in Tables 1  and 2 . Overall, the anemic group had higher rates of coronary artery disease, coronary artery bypass surgery, and ischemic cardiomyopathy. Baseline echocardiographic measurements were similar for both groups (see Table 3 ).
Survival and heart failure hospitalizations
Of the 300 patients, 146 patients experienced the primary composite endpoint within the 2-year follow-up period. One hundred twenty-three patients were hospitalized for heart failure, 13 patients had a heart transplant (median 148 days, range 33-667 days), four patients had an LVAD (one of whom later had a heart transplant), and 22 patients died. Patients with anemia prior to device implant had a significantly increased risk of both the combined primary endpoint and the secondary endpoint (HR 1.6 [1.2-2.3] for the primary endpoint and 1.9 [1.2-3.0] for the secondary endpoint, see Kaplan-Meier curves in Fig. 1a, b) . Exploratory analysis showed that Hb was an independent predictor of the primary composite endpoint both when analyzed as a continuous variable and by quartiles (p = 0.015). Estimated glomerular filtration rate (GFR) improved slightly from preimplant to follow-up (median change 2.8 (interquartile range (IQR) 16) mL/min/ 1.73 m 2 for non-anemic and 1.7 (IQR 14) mL/min/1.73 m 2 for anemic patients, p=0.54). There was a trend for correlation Values are number (percentage) for categorical variables, means±SD for normally distributed variables, and median (interquartile range) for nonnormally distributed variables NYHA New York Heart Association classification of heart failure, LBBB left bundle branch block, CAD coronary artery disease, CABG coronary artery bypass grafting, ICD implantable defibrillator revealed only a moderate correlation between baseline creatinine and anemia (r=0.19). Therefore, given the lack of effect modification, the final model did not include the interaction term. Additional interaction analyses also showed that the effect of anemia was independent of gender (p value for interaction=0.17) and of age (p=0.27), which is also visualized in Kaplan-Meier analysis ( Supplementary Fig. Fig. 3 ). For patients with ischemic cardiomyopathy, anemia was a strong predictor of worse outcome (p=0.001), whereas for patients with dilated cardiomyopathy, there was no significant difference in outcome associated with baseline anemia (HR 1.4 [0.7-2.8], p=0.43).
The results of the dynamic component of the study analyzing the predictive value of change in Hb level from baseline to follow-up are shown in Fig. 2 . When stratified by quartiles of Hb change, patients with the largest decrease in Hb (≤−1.00 g/ dL) had markedly lower event-free survival (log-rank test p= 0.014) and increased hazard for the composite endpoint (HR 1.840, 95 % CI 1.129-2.999) when compared to the remaining quartiles. The patients with anemia at baseline had a significant increase in Hb levels from baseline to follow-up (average increase 0.55±1.6 g/dL, p<0.001), although followup Hb levels in patients with baseline anemia were still on average lower than the mean follow-up Hb levels for patients without anemia at baseline (11.8 vs. 13.5 g/dL, p<0.001).
Left ventricular reverse remodeling
In the whole cohort, the mean values of left ventricular ejection fraction improved from 23.6 ± 6.8 to 30.7 ± 12.1 % (p<0.001), LVESD decreased from 55.0±9 to 51.1±11 mm (p<0.001), and LVEDD decreased from 62.9±9 to 59.9± 10 mm (p<0.001). There were no differences in the degree of LV reverse remodeling between anemic and non-anemic patients (Table 3) .
Discussion
The results of our study show that both baseline anemia and a decrease in Hb level during the early period after device implant are suggestive of poorer clinical outcomes in patients with heart failure undergoing CRT implantation. In addition, we show that there was no significant difference in improvement of left ventricular dimensions and ejection fraction at 6 months after CRT implant between patients with and without anemia at baseline. These findings suggest that although the prognosis per se is worse for patients with baseline anemia, the positive remodeling benefit of CRT is not attenuated among these patients.
Anemia in heart failure patients
The importance of anemia in the pathophysiology of heart failure has been highlighted over the last several years. Anemia is common in heart failure patients, the most frequent cause of the anemia being from Bchronic disease,^even though a subset of these patients may have iron deficiency anemia as well [16] . Increasing age, coronary artery disease, chronic renal disease, atrial fibrillation, female gender, diabetes, and elevated systolic blood pressure have all been [14, 17, 18] . Even though there is no direct relation between hemoglobin level and LV ejection fraction, heart failure in itself has been implicated in worsening anemia through several mechanisms including impaired erythropoietin (Epo) production related to systemic inflammation, blunted erythropoiesis secondary to cytokine activation, as well as reduced renal blood flow due to lower cardiac output [9, 16] . Anemia has also been proposed to worsen HF; patients with chronic anemia have lower systemic vascular resistance, which could result in a negative activation of the reninangiotensin-aldosterone system and increased salt and water Fig. 1 a Kaplan-Meier estimate of time to the primary composite endpoint, stratified by preimplant anemia. Kaplan-Meier curves show cumulative survival free from the composite endpoint of heart failure hospitalization, left ventricular assist device (LVAD), heart transplant or death. p Value is for log-rank test comparison between the two groups. b Kaplan-Meier estimate of time to the secondary endpoint (overall survival free from heart transplant or left ventricular assist device), stratified by preimplant anemia. p Value is for log-rank test comparison between the two groups retention, culminating in pathologic LV remodeling [9] . Indeed, a recent study has suggested a direct link between anemia and cardiac remodeling, based on the findings that decreases in Hb levels were independently associated with increases in LV size and other echocardiographic markers of LV remodeling, as well as increased levels of NT-ProBNP and troponin T [18, 19] .
Anemia and CRT
In the abovementioned studies, only a small subset of the patients has had concomitant CRT treatment, and even though the working model of the pathophysiological cycle of HF and anemia has been proposed, anemia and the dynamic changes of Hb levels postoperatively have not been studied before as a predictor of adverse outcomes in patients treated with CRT. The results of this study show that baseline Hb levels could add independent prognostic information and thus be useful in determining how patients would fare after CRT. It should be noted that although our study used the WHO definition of anemia to dichotomize anemic and non-anemic patients for the sake of prognostication, exploratory analysis showed that Hb was an independent predictor of the primary composite endpoint also when analyzed as a continuous variable, implying that in clinical practice, a significant decrease in Hb can have prognostic value even though the threshold for anemia is not met. Further subanalyses showed that the results seem to be valid in most subsets of patients, with the exclusion of patients with dilated cardiomyopathy. A possible explanation for the greater discriminatory value in ischemic patients can be the association to blood-thinning agents that are more frequently used for these patients. Vulnerable patients with heart failure who also are on blood-thinning drugs may be more prone to occult bleeding, which, in turn, may result in a worse prognosis for long-term outcome. Furthermore, our study shows that worsening anemia over the first-year postimplant is associated with poorer clinical outcomes after CRT. The patients that had a significant decrease in Hb level (≥1.00 g/dL) in the postoperative period had a worse prognosis. Substantial perioperative bleeding is extremely unusual for CRT procedures, and therefore, the most likely reasons for hemoglobin decrease in the first 6 months postoperative period include gastrointestinal bleeding or worsening secondary anemia due to progression of heart failure. Given the association with renal function, it is likely that secondary anemia due to renal failure could be a significant contributor. This, in turn, could be caused by progression of heart failure. Regardless, we believe that it would be beneficial to assess hemoglobin levels as part of standard follow-up procedures after device implantation, and in case of deteriorating Hb values, the patient should merit further attention by a heart failure specialist. Hemoglobin level can be determined by a simple CBC, and assessing baseline and postimplant hemoglobin levels for CRT candidates could be a costeffective way of improving risk determination.
In terms of LV reverse remodeling, there was no significant difference in baseline to follow-up changes in LVEF, LVESV, or LVEDV between the anemic and non-anemic populations. This shows that LV reverse remodeling most likely did not confound the results of the study and implies that even though the overall prognosis is worse in anemic patients, they should not be deferred from CRT therapy since they seem to derive the same physiological cardiac remodeling benefit as the nonanemic patients. Indeed, anemic patients showed a significantly better improvement on Hb levels at follow-up, as compared to non-anemic patients. These patients with a combination of advanced heart failure and anemia most likely have a significant secondary cardiac component of their anemia, and when this component is improved on (post-CRT implant), they show increasing Hb levels [20] . The focus of attention should in particular be on the patients with low hemoglobin levels to start with and with continuing decrease in hemoglobin levels at postimplantation follow-up visits. In addition to further attention from a heart failure specialist, treatment with iron or erythropoietin may be helpful, but to establish this would require a prospective randomized trial, and results from recently published studies have so far been contradictory [21] .
Limitations
This study was done as a single-center study on patients who visited the Massachusetts General Hospital Arrhythmia Service, a tertiary care center. The study represents a consecutive real-life cohort but was retrospective and without a non-CRT control group, and as a result, there may be an inherent selection bias in the way patients were accepted for procedures. It is possible that there was an inclusion bias based on the criteria that patients needed to have Hb measurements at baseline and follow-up, even though our analyses showed no major differences between included and excluded patients; most baseline variables did not differ significantly as compared to the patients that were not included in the study cohort, but hypertension (67 vs. 79 %, p=0.001) and diabetes (34 vs. 45 %, p=0.01) were slightly more common in the study cohort, and more patients in this group were on treatment with loop diuretics (91 vs. 83 %, p=0.01).
The baseline characteristics of the anemic and non-anemic populations were not perfectly matched; overall, the anemic population was older, more commonly male, with higher rates of CAD, CABG, ischemic cardiomyopathy, and renal dysfunction. However, anemia was still a predictor of the primary endpoint when tested within these specific subgroups, with the exception of patients with dilated cardiomyopathy. The results from these subgroup analyses must however be interpreted with caution, since the number of endpoints is limited in each subgroup and the power to make accurate predictions is reduced accordingly.
Even though care was taken to avoid hemoglobin data acquired during the first 48 h of a hospital admission, there is a possibility that overhydration in relation to acute decompensated heart failure episodes could have caused hemodilution in a few of the patients, thereby introducing a bias in the data. Data regarding the etiology of anemia and the exact cause of death were not available for the analyses in this study. Furthermore, data regarding any blood transfusions in between the baseline visit and follow-up visit for all patients were not available. Data regarding anticoagulant use was not available, but adequate adjustments were made for atrial fibrillation (the main indication for anticoagulants) and ischemic cardiomyopathy (the main indication for thrombocyte inhibitors such as clopidogrel). In order to establish the causal relationship between secondary anemia, reverse remodeling, and prognostic outcome in CRT-treated patients, prospective randomized trials will be needed.
Conclusion
The current study offers insight into the prognostic role of baseline anemia and subsequent changes in hemoglobin after implant in patients undergoing CRT. Baseline anemia and postimplantation significant declines in Hb levels are both indicative of a worse 2-year prognosis, and this should be taken into account in the preoperative and postoperative evaluation. However, anemic patients show similar magnitudes of reverse remodeling in response to CRT, indicating a favorable effect of the treatment. More work needs to be done to determine if there is a causal effect of CRT on the level of hemoglobin in HF in patients with anemia and if treatment with erythropoietin or iron substitution may improve outcomes in anemic patients with heart failure treated with CRT.
